With a $2.47 million gift from Novo Nordisk Inc., Live HealthSmart Alabama is applying its holistic health model in Selma, ...

While the attention of late has been firmly focused on Novo Nordisk's obesity and diabetes business ... designed by reusing excess soil, wooden materials and other sustainable resources ...

Taken together, the system can support patients with medication reminders, education ... existing diabetes management ecosystems." Lilly is trying to stay ahead of rivals Novo Nordisk and Sanofi ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

And regarding the slower-than-expected sales in the industry, Novo Nordisk's work goes beyond diabetes and obesity, which are currently its core areas. The drugmaker has been looking to diversify ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Novo Nordisk reported turnover from obesity treatments soared by 57 per cent to 65.1 billion Danish kroner last year, largely driven by strong demand in the United States.